Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
519
archived clinical trials in
Bronchitis

Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Decatur, GA
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Olathe, KA
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Olathe, KA
Click here to add this to my saved trials
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Rochester, MN
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Brooklyn, NY
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Mineola, NY
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Mineola, NY
Click here to add this to my saved trials
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Asheville, NC
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Asheville, NC
Click here to add this to my saved trials
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Portland, OR
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Doylestown, PA
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Doylestown, PA
Click here to add this to my saved trials
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Greenville, SC
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Greenville, SC
Click here to add this to my saved trials
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Edinburg, TX
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Edinburg, TX
Click here to add this to my saved trials
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Tyler, TX
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Tyler, TX
Click here to add this to my saved trials
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated:  9/4/2017
Clinical Research Facility
mi
from
Skokie, IL
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated: 9/4/2017
Clinical Research Facility
mi
from
Skokie, IL
Click here to add this to my saved trials
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated:  9/6/2017
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated: 9/6/2017
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated:  9/6/2017
Stanford University
mi
from
Stanford, CA
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated: 9/6/2017
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated:  9/6/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated: 9/6/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated:  9/6/2017
National Cancer Institute Experimental Transplantation & Immunology Branch
mi
from
Bethesda, MD
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated: 9/6/2017
National Cancer Institute Experimental Transplantation & Immunology Branch
mi
from
Bethesda, MD
Click here to add this to my saved trials
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated:  9/6/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated: 9/6/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated:  9/6/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated: 9/6/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated:  9/6/2017
Siteman Cancer Center at Washington University
mi
from
Saint Louis, MO
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated: 9/6/2017
Siteman Cancer Center at Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated:  9/6/2017
Vanderbilt University
mi
from
Nashville, TN
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated: 9/6/2017
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated:  9/6/2017
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated: 9/6/2017
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated:  9/6/2017
Medical College of Wisconsin
mi
from
Milwaukee, WI
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated: 9/6/2017
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated:  9/6/2017
Weill-Cornell Medical College
mi
from
New York, NY
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated: 9/6/2017
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
Stanford University
mi
from
Palo Alto, CA
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
University of California, San Diego
mi
from
San Diego, CA
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
Yale University
mi
from
New Haven, CT
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
University of Miami
mi
from
Miami, FL
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
Emory University
mi
from
Atlanta, GA
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
Indiana University
mi
from
Indianapolis, IN
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
University of Iowa
mi
from
Iowa City, IA
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
Tufts Medical Center
mi
from
Boston, MA
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
Wayne State University
mi
from
Detroit, MI
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
University of New Mexico
mi
from
Albuquerque, NM
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
University of New Mexico
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
University of Rochester
mi
from
Rochester, NY
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
Wake Forest University
mi
from
Charlotte, NC
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
Wake Forest University
mi
from
Charlotte, NC
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
RTI International
mi
from
Durham, NC
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
RTI International
mi
from
Durham, NC
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
Duke University
mi
from
Durham, NC
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
Cincinnati Children's Medical Center
mi
from
Cincinnati, OH
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
Cincinnati Children's Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
Case Western Reserve University, Rainbow Babies and Children's Hospital
mi
from
Cleveland, OH
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
Case Western Reserve University, Rainbow Babies and Children's Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
Brown University, Women & Infants Hospital of Rhode Island
mi
from
Providence, RI
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
Brown University, Women & Infants Hospital of Rhode Island
mi
from
Providence, RI
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
University of Tennessee
mi
from
Memphis, TN
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
University of Tennessee
mi
from
Memphis, TN
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
UT Southwestern Medical Center
mi
from
Dallas, TX
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
UT Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
University of Utah
mi
from
Salt Lake City, UT
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Vitamin A Supplementation for Extremely-Low-Birth-Weight Infants
Randomized Trial of Vitamin A Supplementation for Extremely-Low-Birth-Weight
Status: Enrolling
Updated:  9/22/2017
Stanford University
mi
from
Palo Alto, CA
Vitamin A Supplementation for Extremely-Low-Birth-Weight Infants
Randomized Trial of Vitamin A Supplementation for Extremely-Low-Birth-Weight
Status: Enrolling
Updated: 9/22/2017
Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Vitamin A Supplementation for Extremely-Low-Birth-Weight Infants
Randomized Trial of Vitamin A Supplementation for Extremely-Low-Birth-Weight
Status: Enrolling
Updated:  9/22/2017
Yale University
mi
from
New Haven, CT
Vitamin A Supplementation for Extremely-Low-Birth-Weight Infants
Randomized Trial of Vitamin A Supplementation for Extremely-Low-Birth-Weight
Status: Enrolling
Updated: 9/22/2017
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Vitamin A Supplementation for Extremely-Low-Birth-Weight Infants
Randomized Trial of Vitamin A Supplementation for Extremely-Low-Birth-Weight
Status: Enrolling
Updated:  9/22/2017
George Washington University
mi
from
Washington, D.C.,
Vitamin A Supplementation for Extremely-Low-Birth-Weight Infants
Randomized Trial of Vitamin A Supplementation for Extremely-Low-Birth-Weight
Status: Enrolling
Updated: 9/22/2017
George Washington University
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Vitamin A Supplementation for Extremely-Low-Birth-Weight Infants
Randomized Trial of Vitamin A Supplementation for Extremely-Low-Birth-Weight
Status: Enrolling
Updated:  9/22/2017
University of Miami
mi
from
Miami, FL
Vitamin A Supplementation for Extremely-Low-Birth-Weight Infants
Randomized Trial of Vitamin A Supplementation for Extremely-Low-Birth-Weight
Status: Enrolling
Updated: 9/22/2017
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Vitamin A Supplementation for Extremely-Low-Birth-Weight Infants
Randomized Trial of Vitamin A Supplementation for Extremely-Low-Birth-Weight
Status: Enrolling
Updated:  9/22/2017
Emory University
mi
from
Atlanta, GA
Vitamin A Supplementation for Extremely-Low-Birth-Weight Infants
Randomized Trial of Vitamin A Supplementation for Extremely-Low-Birth-Weight
Status: Enrolling
Updated: 9/22/2017
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials